Winton Group LTD Incyte Corp Transaction History

Winton Group LTD

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$52.16 - $64.19 $105,154 - $129,407	-2,016 Reduced 36.53%	3,502 $219,000
Q3 2023 Nov 13, 2023	BUY	$57.77 - $65.93 $318,774 - $363,801	5,518 New	5,518 $318,000
Q1 2023 May 12, 2023	SELL	$70.23 - $86.01 $1.1 Million - $1.35 Million	-15,710 Reduced 23.15%	52,156 $3.77 Million
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $307,885 - $385,476	4,583 Added 7.24%	67,866 $5.45 Million
Q3 2022 Nov 10, 2022	SELL	$66.18 - $82.86 $979,530 - $1.23 Million	-14,801 Reduced 18.96%	63,283 $4.22 Million
Q2 2022 Aug 10, 2022	BUY	$66.18 - $83.18 $1.44 Million - $1.81 Million	21,705 Added 38.5%	78,084 $5.93 Million
Q1 2022 May 11, 2022	BUY	$66.02 - $79.71 $1.72 Million - $2.08 Million	26,078 Added 86.06%	56,379 $4.48 Million
Q4 2021 Feb 10, 2022	BUY	$63.34 - $74.11 $1.92 Million - $2.25 Million	30,301 New	30,301 $2.22 Million
Q4 2020 Feb 12, 2021	SELL	$80.74 - $97.7 $1.57 Million - $1.9 Million	-19,466 Closed	0 $0
Q3 2020 Oct 30, 2020	SELL	$85.07 - $109.69 $3.93 Million - $5.07 Million	-46,238 Reduced 70.37%	19,466 $1.75 Million
Q2 2020 Aug 05, 2020	SELL	$74.18 - $108.93 $86,122 - $126,467	-1,161 Reduced 1.74%	65,704 $6.83 Million
Q1 2020 May 11, 2020	BUY	$63.18 - $85.97 $4.22 Million - $5.75 Million	66,865 New	66,865 $4.9 Million
Q4 2017 Feb 13, 2018	SELL	$93.56 - $116.6 $6.68 Million - $8.32 Million	-71,387 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$109.15 - $138.27 $7.44 Million - $9.43 Million	68,189 Added 2132.24%	71,387 $8.33 Million
Q2 2017 Aug 17, 2017	BUY	N/A	3,198	3,198 $403,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.